IN2013CH05537A - - Google Patents

Download PDF

Info

Publication number
IN2013CH05537A
IN2013CH05537A IN5537CH2013A IN2013CH05537A IN 2013CH05537 A IN2013CH05537 A IN 2013CH05537A IN 5537CH2013 A IN5537CH2013 A IN 5537CH2013A IN 2013CH05537 A IN2013CH05537 A IN 2013CH05537A
Authority
IN
India
Prior art keywords
methyl
cognition
schizophrenia
bromophenyl
piperazinyl
Prior art date
Application number
Inventor
Ramakrishna Nirogi
Rama Sastri Kambhampati
Anil Karbhari Shinde
Venkateswarlu Jasti
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HK16114655.9A priority Critical patent/HK1226396B/en
Priority to BR112016010788-8A priority patent/BR112016010788B1/en
Priority to ES14725245.6T priority patent/ES2638856T3/en
Priority to JP2016535680A priority patent/JP6151453B2/en
Priority to HUE14725245A priority patent/HUE036008T2/en
Priority to IN5537CH2013 priority patent/IN2013CH05537A/en
Priority to SI201430348T priority patent/SI3077375T1/en
Priority to DK14725245.6T priority patent/DK3077375T3/en
Priority to PCT/IN2014/000109 priority patent/WO2015083179A1/en
Priority to MX2016006629A priority patent/MX364930B/en
Priority to US15/100,489 priority patent/US9540321B2/en
Priority to EP14725245.6A priority patent/EP3077375B1/en
Priority to NZ719671A priority patent/NZ719671A/en
Priority to RS20170853A priority patent/RS56323B1/en
Priority to PT147252456T priority patent/PT3077375T/en
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Priority to KR1020167013965A priority patent/KR101808792B1/en
Priority to AP2016009224A priority patent/AP2016009224A0/en
Priority to MEP-2017-193A priority patent/ME02843B/en
Priority to HRP20171245TT priority patent/HRP20171245T1/en
Priority to CA2929309A priority patent/CA2929309C/en
Priority to PL14725245T priority patent/PL3077375T3/en
Priority to LTEP14725245.6T priority patent/LT3077375T/en
Priority to AU2014358682A priority patent/AU2014358682B2/en
Priority to EA201691161A priority patent/EA028038B1/en
Priority to SM20170408T priority patent/SMT201700408T1/en
Priority to CN201480065601.9A priority patent/CN105814020B/en
Publication of IN2013CH05537A publication Critical patent/IN2013CH05537A/en
Priority to ZA2016/02954A priority patent/ZA201602954B/en
Priority to IL245619A priority patent/IL245619B/en
Priority to CY20171100904T priority patent/CY1119298T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

A process suitable for adoption to large scale manufacture of l-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-l-piperazinyl)methyl]-lH-indole dimesylate monohydrate, which is a selective 5-HT6 receptor antagonist intended for the symptomatic treatment of Alzheimer's disease and other disorders of memory and cognition like Attention deficient hyperactivity, Parkinson's and Schizophrenia.
IN5537CH2013 2013-12-02 2014-02-20 IN2013CH05537A (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
PT147252456T PT3077375T (en) 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
ES14725245.6T ES2638856T3 (en) 2013-12-02 2014-02-20 Process for large-scale production of 1 - [(2-bromophenyl) sulfonyl] -5-methoxy-3 - [(4-methyl-1-piperazinyl) methyl] -1H-indole monohydrate dimesylate
JP2016535680A JP6151453B2 (en) 2013-12-02 2014-02-20 Large-scale synthesis of 1-[(2-bromophenyl) sulfonyl] -5-methoxy-3-[(4-methyl-1-piperazinyl) methyl] -1H-indole dimesylate monohydrate
HUE14725245A HUE036008T2 (en) 2013-12-02 2014-02-20 Process for the Production of 1 - [(2-Bromophenyl) sulfonyl] -5-methoxy-3 - [(4-methyl-1-piperazinyl) methyl] -1H-indole dimethylate monohydrate on a large scale scale
IN5537CH2013 IN2013CH05537A (en) 2013-12-02 2014-02-20
SI201430348T SI3077375T1 (en) 2013-12-02 2014-02-20 Process for large scale production of 1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1h-indole dimesylate monohydrate
DK14725245.6T DK3077375T3 (en) 2013-12-02 2014-02-20 PROCEDURE FOR LARGE SCALE PREPARATION OF 1 - [(2-BROMPHENYL) SULPHONYL] -5-METHOXY-3 - [(4-METHYL-1-PIPERAZINYL) METHYL] -1H-INDOL-DIMESYLATE-MONOHYDRATE
PCT/IN2014/000109 WO2015083179A1 (en) 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
MX2016006629A MX364930B (en) 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl] -5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate.
US15/100,489 US9540321B2 (en) 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate
EP14725245.6A EP3077375B1 (en) 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
NZ719671A NZ719671A (en) 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
RS20170853A RS56323B1 (en) 2013-12-02 2014-02-20 Mass Production Process for Monohydrate 1 - [(2-Bromophenyl) Sulfonyl] -5-Methoxy-3 - [(4-Methyl-1-piperazinyl) methyl] -1H-INDOL DIMESILATE
HK16114655.9A HK1226396B (en) 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
MEP-2017-193A ME02843B (en) 2013-12-02 2014-02-20 METHOD OF MASS PRODUCTION OF 1 - [(2-BROMOPHENYL) SULFONYL] -5-METHOXY-3 - [(4-METHYL-1-PIPERAZINYL) METHYL] -1H-INDOL-DIMESYLATE-MONOHYDRATE
BR112016010788-8A BR112016010788B1 (en) 2013-12-02 2014-02-20 PROCESS FOR THE LARGE-SCALE PRODUCTION OF 1-[(2-BROMOPHENYL)SULFONYL]-5-METHOXY-3-[(4-METHYL-1-PIPERAZINYL)METHYL]-1H-INDOLE
AP2016009224A AP2016009224A0 (en) 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
KR1020167013965A KR101808792B1 (en) 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
HRP20171245TT HRP20171245T1 (en) 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
CA2929309A CA2929309C (en) 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
PL14725245T PL3077375T3 (en) 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
LTEP14725245.6T LT3077375T (en) 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
AU2014358682A AU2014358682B2 (en) 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate
EA201691161A EA028038B1 (en) 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
SM20170408T SMT201700408T1 (en) 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
CN201480065601.9A CN105814020B (en) 2013-12-02 2014-02-20 For large-scale production of 1‑[(2‑bromophenyl)sulfonyl]‑5‑methoxy‑3‑[(4‑methyl‑1‑piperazinyl)methyl]‑1H‑indoledimethyl Sulfonate monohydrate method
ZA2016/02954A ZA201602954B (en) 2013-12-02 2016-05-03 Process for large scale production of 1-{(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
IL245619A IL245619B (en) 2013-12-02 2016-05-11 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
CY20171100904T CY1119298T1 (en) 2013-12-02 2017-08-28 PROCEDURE FOR PRODUCING LARGE-SCALE OF 1- (2-BROMOPHENYL) SULFONYL] -5-METHOXY-3 - [(4-METHYL-1-PIPERAZINYL) METHYL] -1H-1 NIDOLEYM MON

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN5537CH2013 IN2013CH05537A (en) 2013-12-02 2014-02-20

Publications (1)

Publication Number Publication Date
IN2013CH05537A true IN2013CH05537A (en) 2015-06-12

Family

ID=54199404

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5537CH2013 IN2013CH05537A (en) 2013-12-02 2014-02-20

Country Status (29)

Country Link
US (1) US9540321B2 (en)
EP (1) EP3077375B1 (en)
JP (1) JP6151453B2 (en)
KR (1) KR101808792B1 (en)
CN (1) CN105814020B (en)
AP (1) AP2016009224A0 (en)
AU (1) AU2014358682B2 (en)
BR (1) BR112016010788B1 (en)
CA (1) CA2929309C (en)
CY (1) CY1119298T1 (en)
DK (1) DK3077375T3 (en)
EA (1) EA028038B1 (en)
ES (1) ES2638856T3 (en)
HK (1) HK1226396B (en)
HR (1) HRP20171245T1 (en)
HU (1) HUE036008T2 (en)
IL (1) IL245619B (en)
IN (1) IN2013CH05537A (en)
LT (1) LT3077375T (en)
ME (1) ME02843B (en)
MX (1) MX364930B (en)
NZ (1) NZ719671A (en)
PL (1) PL3077375T3 (en)
PT (1) PT3077375T (en)
RS (1) RS56323B1 (en)
SI (1) SI3077375T1 (en)
SM (1) SMT201700408T1 (en)
WO (1) WO2015083179A1 (en)
ZA (1) ZA201602954B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3458040B1 (en) * 2016-05-18 2021-01-27 Suven Life Sciences Limited Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist
DK3458039T3 (en) 2016-05-18 2020-09-14 Suven Life Sciences Ltd TRIPLE COMBINATION OF PURE 5-HT6 RECEPTOR ANTAGONISTS, ACETYLCHOLINE ESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONIST
EA036347B1 (en) 2016-05-18 2020-10-29 Сувен Лайф Сайенсиз Лимитед Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors
SMT202100403T1 (en) * 2016-10-03 2021-09-14 Suven Life Sciences Ltd Pharmaceutical compositions of 5-ht6 antagonist
US20210346374A1 (en) * 2016-10-03 2021-11-11 Suven Life Sciences Limited Pharmaceutical compositions of 5-ht6 receptor antagonist
CN110799189A (en) * 2017-07-03 2020-02-14 苏文生命科学有限公司 New uses of pure 5-HT6 receptor antagonists
AU2020398082A1 (en) 2019-12-02 2022-06-16 Suven Life Sciences Limited Treating behavioral and psychological symptoms in dementia patients
JP2023510082A (en) 2019-12-02 2023-03-13 スヴェン・ライフ・サイエンシーズ・リミテッド Methods for treating behavioral and psychological symptoms in patients with dementia
CN111233737B (en) * 2020-03-16 2021-05-11 东莞市东阳光新药研发有限公司 Salts of aromatic heterocyclic derivatives and their uses
CN111362859B (en) * 2020-03-16 2021-05-11 东莞市东阳光新药研发有限公司 Salts of aromatic heterocyclic derivatives and their uses
CN111362858B (en) * 2020-03-16 2021-05-11 东莞市东阳光新药研发有限公司 Salts of aromatic heterocyclic derivatives and their uses
IL301829A (en) 2020-10-13 2023-06-01 Boehringer Ingelheim Int process of reworking

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2749846B1 (en) * 1996-06-17 1998-09-11 Pf Medicament METHANESULFONATE SALT OF ARYLPIPERAZINE DERIVED FROM TRYPTAMINE AND ITS SOLVATES FOR PHARMACEUTICAL USE
JP4559230B2 (en) * 2002-11-28 2010-10-06 スベン ライフ サイエンシズ リミティド Novel N-arylsulfonyl-3-substituted indoles having affinity for serotonin receptors, methods for their preparation, and pharmaceutical compositions containing them
EA009367B1 (en) * 2002-12-18 2007-12-28 Сувен Лайф Сайенсиз Лимитед 5-THIA-5-DIOXO-4b AZA INDENO [2,1-a] INDENE DERIVATIVES HAVING SEROTONIN RECEPTOR AFFINITY
RU2008151724A (en) * 2006-06-12 2010-07-20 Новартис АГ (CH) METHOD FOR PRODUCING N-HYDROXY-3- [4 - [[[2- (2-METHYL-1H-INDOL-3-IL) ETHYL] AMINO] METHYL] PHENYL] Phenyl] -2E-2-PROPENAMIDE SALTS

Also Published As

Publication number Publication date
WO2015083179A1 (en) 2015-06-11
ES2638856T3 (en) 2017-10-24
AP2016009224A0 (en) 2016-05-31
AU2014358682B2 (en) 2016-10-20
EA201691161A1 (en) 2016-09-30
SMT201700408T1 (en) 2017-09-07
US9540321B2 (en) 2017-01-10
JP6151453B2 (en) 2017-06-21
EP3077375B1 (en) 2017-07-19
ZA201602954B (en) 2017-07-26
CY1119298T1 (en) 2018-02-14
US20160297759A1 (en) 2016-10-13
BR112016010788B1 (en) 2023-03-21
HUE036008T2 (en) 2018-06-28
CA2929309A1 (en) 2015-06-11
DK3077375T3 (en) 2017-09-11
JP2016539133A (en) 2016-12-15
CA2929309C (en) 2018-07-03
CN105814020B (en) 2018-04-17
LT3077375T (en) 2017-09-11
SI3077375T1 (en) 2017-10-30
BR112016010788A8 (en) 2018-01-30
ME02843B (en) 2018-01-20
EP3077375A1 (en) 2016-10-12
HRP20171245T1 (en) 2017-10-20
KR20160094945A (en) 2016-08-10
RS56323B1 (en) 2017-12-29
PL3077375T3 (en) 2017-11-30
MX2016006629A (en) 2016-08-08
KR101808792B1 (en) 2017-12-13
HK1226396B (en) 2017-09-29
PT3077375T (en) 2017-09-05
IL245619A0 (en) 2016-06-30
CN105814020A (en) 2016-07-27
NZ719671A (en) 2017-03-31
AU2014358682A1 (en) 2016-06-02
EA028038B1 (en) 2017-09-29
IL245619B (en) 2018-12-31
MX364930B (en) 2019-05-14

Similar Documents

Publication Publication Date Title
IN2013CH05537A (en)
EP2990199A4 (en) PROCESS FOR PRODUCING POROUS POLYIMIDE FILM, POROUS POLYIMIDE FILM, AND SEPARATOR USING THE SAME
EP2998389A4 (en) PROCESS FOR OBTAINING STRATIFORM CELL CULTURE
EP2915906A4 (en) PROCESS FOR PRODUCING ELECTRODE FOR ELECTROLYSIS
JO3070B1 (en) Factors for the treatment of disorders include the modification of ryanodin receptors
BR112016006154A2 (en) indole and indazole derivatives
EP2963064A4 (en) PROCESS FOR PRODUCING A BLOCK COPOLYMER OF PROPYLENE
GB201602297D0 (en) Process for the synthesis of stable amorphous ibrutinib
EP2947046A4 (en) PROCESS FOR PRODUCING HYDROGEN
EP2987854A4 (en) MICROORGANISMS PRODUCING L-TRYPTOPHAN AND PROCESS FOR PRODUCING L-TRYPTOPHANE USING THE SAME
EP3467014A4 (en) PROCESS FOR PRODUCING POROUS BODY
EP2421876A4 (en) HIGHLY SELECTIVE PROCESS FOR THE PRODUCTION OF ORGANODIPHOSPHITES
EP3384917A4 (en) PROCESS FOR PRODUCING HYALURONIDASE CONJUGATE WITH POLYETHYLENE PIPERAZINE DERIVATIVES AND USE OF THE CONJUGATE OBTAINED
EP2933226A4 (en) DEVICE FOR PRODUCING HYDROGEN
ZA201603839B (en) Process for the production of synthesis gas
FR3000737B1 (en) PROCESS FOR PRODUCING HYDROGEN
NZ728907A (en) Active metabolite of 1-[(2-bromophenyl) sulfonyl]-5-methoxy-3- [(4-methyl-1-piperazinyl) methyl]-1h-indole dimesylate monohydrate and dimesylate dihydrate salt of active metabolite
MX366033B (en) Process for large scale production of 1-isopropyl-3-{5- [1-(3-methoxypropyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}- 1h-indazole oxalate.
FR3021316B1 (en) PROCESS FOR OBTAINING BORAZANE
FR3021317B1 (en) PROCESS FOR OBTAINING BORAZANE
PL407576A1 (en) Amorphous imatinib mesylate hemihydrate
EP2832684A4 (en) PROCESS FOR PRODUCING HYDROGEN
IN2013MU02612A (en)
IN2013MU03838A (en)
CN302384334S (en) Basin Faucet(12363)